Cargando…
Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
OBJECTIVE: The aim of the current study was to evaluate the 2-year cost-utility ratio between tapering conventional synthetic disease-modifying antirheumatic drugs (csDMARD) first followed by the tumour necrosis factor (TNF)-inhibitor, or vice versa, in patients with rheumatoid arthritis (RA). METHO...
Autores principales: | van Mulligen, Elise, Weel, Angelique E, Kuijper, Tjallingius Martijn, Denissen, N H A M, Gerards, Andreas H, de Jager, Mike H, Lam-Tse, Wai-Kwan, Hazes, J M, van der Helm-van Mil, Annette, de Jong, Pascal Hendrik Pieter, Luime, Jolanda J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677489/ https://www.ncbi.nlm.nih.gov/pubmed/32907801 http://dx.doi.org/10.1136/annrheumdis-2020-217528 |
Ejemplares similares
-
Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020) -
DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020) -
Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023) -
Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023) -
What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data
por: Mangnus, Lukas, et al.
Publicado: (2015)